VIDEO: Long-term trials support earlier MS treatment with Ocrevus

BOSTON — More than half of patients with early MS had no disease progression over 9 years when taking Ocrevus, according to Ashish Pradhan, MD, in this Healio video.

Results from two long-term studies of Ocrevus (ocrelizumab, Genentech) were presented at the American Academy of Neurology meeting, Pradhan, executive director of neuroimmunology for Genentech said.

OPERA II study results showed that patients with early but relapsing MS had no evidence of disease activity – which includes relapses, disability and MRI activity – over the 9 years of the study, he said.

Reference:

• Hauser S, et al. Delayed signs of early disability progression after 8.5 years of Ocrelizumab treatment in patients with relapsing multiple sclerosis. Presented at: American Academy of Neurology annual meeting; April 22-27, 2023; Boston.